NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.43 +0.07 (+0.49 %) (As of 04/6/2020 08:30 AM ET) Add Compare Share Today's Range$14.25Now: $14.43▼$14.8550-Day Range$11.34MA: $16.08▼$20.3752-Week Range$3.52Now: $14.43▼$21.93Volume687,360 shsAverage Volume1.93 million shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/ABeta1.45 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.29, Aurinia Pharmaceuticals has a potential upside of 68.3% from its current price of $14.43.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesAurinia Pharmaceuticals has received 509 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAurinia Pharmaceuticals has received 332 “underperform” votes. (Add your “underperform” vote.)Community SentimentAurinia Pharmaceuticals has received 60.52% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote “Outperform” if you believe AUPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Institutions48.13% of the stock of Aurinia Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to decrease by -67.91% in the coming year, from ($1.34) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH Previous Symbol CUSIPN/A CIK1600620 Webhttp://www.auriniapharma.com/ Phone250-744-2487Debt Debt-to-Equity RatioN/A Current Ratio27.90 Quick Ratio27.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$320,000.00 Price / Sales5,064.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book5.89Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-123,850,000.00 Net Margins-38,941.82% Return on Equity-46.84% Return on Assets-39.12%Miscellaneous Employees39 Outstanding Shares112,300,000Market Cap$1.62 billion Next Earnings Date5/12/2020 (Estimated) OptionableOptionable Receive AUPH News and Ratings via Email Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AUPH Rates by TradingView Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions How has Aurinia Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUPH stock has increased by 2.3% and is now trading at $14.43. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals. When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Aurinia Pharmaceuticals. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.08. The biotechnology company earned $0.03 million during the quarter, compared to analysts' expectations of $0.04 million. Aurinia Pharmaceuticals had a negative net margin of 38,941.82% and a negative return on equity of 46.84%. View Aurinia Pharmaceuticals' earnings history. What price target have analysts set for AUPH? 7 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $14.00 to $32.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $24.29 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals. Has Aurinia Pharmaceuticals been receiving favorable news coverage? News headlines about AUPH stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAurinia Pharmaceuticals. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 5,351,000 shares, an increase of 6.6% from the February 27th total of 5,020,000 shares. Based on an average trading volume of 1,716,400 shares, the days-to-cover ratio is presently 3.1 days. Approximately 6.3% of the company's stock are sold short. View Aurinia Pharmaceuticals' Current Options Chain. Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Forty Seven (FTSV), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Evotec (EVTCY), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS) and Zai Lab (ZLAB). What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Novavax (NVAX), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the following people: Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault CPA, C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Richard M. Glickman, Advisor (Age 61)Dr. Neil Solomons M.D., Chief Medical Officer What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH." How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUPH stock can currently be purchased for approximately $14.43. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of $1.62 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe. View additional information about Aurinia Pharmaceuticals. What is Aurinia Pharmaceuticals' official website? The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio?
